Rockwell to launch phase 3 studies of iron-fortified dialysate. PDF Print
Nephronline: Renal biopharmaceutical company Rockwell Medical Inc. announced that the clinical research divisions of the two largest dialysis companies in North America have signed agreements to participate in the company's pivotal Phase 3 CRUISE studies using Soluble Ferric Pyrophosphate (SFP) as a continuous iron replacement therapeutic.

...

 
Share |
Copyright © 2026 Global Dialysis. All Rights Reserved.